Immune control of HIV-1 infection after therapy interruption: Immediate versus deferred antiretroviral therapy

BMC Infectious Diseases

Volumn 9, Issue , 2009, Pages 172-

  Paci, Paola ^a   Carello, Rossella ^b,c   Bernaschi, Massimo ^a   D'Offizi, Gianpiero ^b   Castiglione, Filippo ^a  

^a CNR   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; EARLY INTERVENTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; MATHEMATICAL ANALYSIS; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; COMPUTER SIMULATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PILOT PROJECTS; RNA, VIRAL; TIME FACTORS; VIREMIA; YOUNG ADULT;

EID: 70450225444     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-9-172     Document Type: Article

References (34)

1. Ahdieh-Grant1 L, Yamashita TE, Phair JP, Detels R, Wolinsky SM, Margolick JB, Rinaldo CR, Jacobson LP. When to Initiate Highly Active Antiretroviral Therapy: A Cohort Approach. Am J Epidemiol 2003, 157:738-746. 10.1093/aje/kwg036, 12697578.
2. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debré P, Leibowitch J. Positive Effects of Combined Antiretroviral Therapy on CD4+ T Cell Homeostasis and Function in Advanced HIV Disease. Science 1997, 277:112-116. 10.1126/science.277.5322.112, 9204894.
3. Yamashita T, Phair J, Muñoz A, Margolick J, Detels R, O'Brien S, Mellors J, Wolinsky S, Jacobson L. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001, 15:735-745. 10.1097/00002030-200104130-00009, 11371688.
4. Quinn T, Wawer M, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan M, Lutalo T, Gray R. Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1. N Engl J Med 2000, 342:921-929. 10.1056/NEJM200003303421303, 10738050.
5. DHHS Guidelines for the use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescent. 2008, , http://aidsinfo.nih.gov
6. Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange J, Prins J. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 2008, 22:1583-1588. 10.1097/QAD.0b013e328305bd77, 18670217.
7. Opravil M, Ledergerber B, Furrer H, Hirschel B, Imhof A, Gallant S, Wagels T, Bernasconi E, Meienberg F, Rickenbach M, Weber R. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l. AIDS 2002, 16:1371-1381. 10.1097/00002030-200207050-00009, 12131214.
8. Castiglione F, Poccia F, D'Offizi G, Bernaschi M. Mutation, Fitness, Viral Diversity, and Predictive Markers of Disease Progression in a Camputational Model of HIV Type 1 infection. AIDS Res Hum Retrovirus 2004, 20(12):1314-1323.
9. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17:1871-1879. 10.1097/00002030-200309050-00005, 12960819.
10. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997, 387:188-191. 10.1038/387188a0, 9144290.
11. Herz A, Bonhoeffer S, Anderson R, May R, Nowak M. Viral Dynamics in vivo: Limitations on estimates of intracellular delay and virus decay. Proc Natl Acad Sci USA 1996, 93:7247-7251. 10.1073/pnas.93.14.7247, 38968, 8692977.
12. Stranford SA, Martinez-Mariño JCOB, Busch M, Hecht FM, Kahn J, Levy JA. Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving higly active antiretroviral therapy during primary infection. Proc Natl Acad Sci USA 2001, 98:597-602. 10.1073/pnas.021550598, 14633, 11136234.
13. Maldarelli F, Palmer S, King M, Wiegand A, Polis M, Mican J, Kovacs J, Davey R, Rock-Kress D, Dewar R, Liu S, Metcalf J, Rehm C, Brun S, Hanna G, Kempf D, Coffin J, Mellors J. Art Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia. Plos Phathog 2007, 3(4):484-488.
14. Hel Z, McGhee J, Mestecky J. HIV infection: firts battle decides the war. TRENDS Immunol 2006, 27(6):274-281. 10.1016/j.it.2006.04.007, 16679064.
15. Rosenberg E, Altfeld M, Poon S, Phillips M, Wilkes B, Eldridge R, Robbins G, D'Aquila R, Goulder P, Walker B. Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523-526. 10.1038/35035103, 11029005.
16. Oxenius A, Price D, PJ E, O'Callaghan C, Kelleher A, Whelan J, Sontag G, Sewell A, Phillips R. Early highly active antiretroviral therapy for acute HIV-1 infection preserves function of CD8+ and CD4+T lymphocytes. Proc Natl Acad Sci USA 2000, 97(7):3382-3387. 10.1073/pnas.97.7.3382, 16248, 10737796.
17. Lempicki R, Kovacs J, Baseker M, Adelsberger J, Dewar R, Natarajan V, Bosche MC, Metcalf JA, Stevens RA, Lambert LA. Impact of HIV-1 infection and higly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc Natl Acad Sci USA 2000, 97(25):13778-13783. 10.1073/pnas.250472097, 17652, 11095734.
18. Harrer T, Harrer E, Kalams S, Elbeik T, Staprans S, Feinberg M, Cao Y, Ho D, Yilma T, Caliendo A. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996, 12(7):585-592. 10.1089/aid.1996.12.585, 8743084.
19. Klein M, van Baalen C, Holwerda A, Kerkhof Garde S, Bende R, Keet I, Eeftinck-Schattenkerk J, Osterhaus A, Schuitemaker H, Miedema F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995, 181:1365-1372. 10.1084/jem.181.4.1365, 2191947, 7699324.
20. D'Offizi Gioia C, Corpolongo A, Martini F, Paganelli R, Volpi I, Sacchi A, Tozzi V, Narciso P, Poccia F. An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects. Int J Immunopathol Pharmacol 2007, 20(3):473-485.
21. Poccia F, Gioia C, Corpolongo A, D'Offizi G, Narcisco P, Martini F. CD8 T cell response to Nef peptides and HIV type 1 control in early-treated patients after antiretroviral treatment interruption. AIDS Res Hum Retroviruses 2006, 22(4):330-332. 10.1089/aid.2006.22.330, 16623635.
22. Bernaschi M, Castiglione F. Design and implementation of an Immune System Simulator. Comp Biol Med 2001, 31(5):303-331.
23. Castiglione F, Pappalardo F, Bernaschi M, Motta S. Optimization of HAART with genetic algorithms and agent based models of HIV infection. Bioinformatics 2007, 23(24):3350-3355. 10.1093/bioinformatics/btm408, 17942443.
24. Castiglione F, Duca K, Jarrah A, Laubenbacher R, Luzuriaga K, Hochberg D, Thorley-Lawson D. Simulating Epstein Barr Virus Infection with C-ImmSim. Bioinformatics 2007, 23:1371-1377. 10.1093/bioinformatics/btm044, 17341499.
25. Pappalardo F, Lollini P, Castiglione F, Motta S. Modelling and Simulation of Cancer Immunoprevention Vaccine. Bioinformatics 2005, 21(12):2891-2897. 10.1093/bioinformatics/bti426, 15817697.
26. Farmer J, Packard N, Perelson A. The immune system, adaptation and machine learning. Physica D 1986, 22:187-204.
27. Castiglione F, Bernaschi M. HIV-1 strategies of immune evasion. Int J Mod Phys C 2005, 16(12):1869-1879.
28. Segovia-Juarez JL, Ganguli S, Kirschner D. Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. Journal of Theoretical Biology 2004, 231(3):357-376. 10.1016/j.jtbi.2004.06.031, 15501468.
29. Francis K, Palsson BO. Effective intercellular communication distances are determined by the relative time constants for cyto/chemokine secretion and diffusion. Proc Natl Acad Sci USA 1997, 94(23):12258-12262. 10.1073/pnas.94.23.12258, 24899, 9356436.
30. Miller MJ, Wei SH, Cahalan MD, Parker I. T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc Natl Acad Sci USA 2004, 101:998-1003. 10.1073/pnas.0306407101, 327133, 14722354.
31. Scott-Algara D, Aboulker JP, Durier C, Badell E, Marcellin F, Prud'homme M, Jouanne C, Meiffredy V, Brun-Vezinet F, Pialoux G, Raffi F. CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART. Clin Exp Immunol 2001, 126(2):295-303. 10.1046/j.1365-2249.2001.01680.x, 1906208, 11703374.
32. Mezzaroma I, Carlesimo M, Pinter E, Alario C, Sacco DG, Muratori, Bernardi M, Paganelli R, Aiuti F. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS 1999, 13(10):1187-1193. 10.1097/00002030-199907090-00006, 10416521.
33. Castiglione F, Poccia F, D'Offizi G, Bernaschi M. AIDS Res Hum Retrovirus 2004, 20(12):1314-1323.
34. Hel Z, McGhee J, Mestecky J. TRENDS Immunol 2006, 27(6):274-281. 10.1016/j.it.2006.04.007, 16679064.